Co-creating health for humanity: New trends in pharmaceutical interorganizational deals

Discovering new drugs has become increasingly rare for independent large pharmaceutical companies in recent times. Almost 60% of new drugs are discovered through mergers and acquisitions and drug licensing. Now, researchers shed light on the recent trends of spinouts from academia and investments in the U.S.A and Europe, foreshadowing a promising shift in the industry’s interorganizational deal networks to improve research and development productivity in the future.